GeneDx Iceland at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

GeneDx Iceland at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
GI GeneDx Iceland Reykjavík, Iceland	1 presenter
Subsidiary GeneDx provides clinical exome and genome testing, expert interpretation, and genomic data. It serves healthcare providers, health systems, patients, and biopharma partners. Partnered with Beren Therapeutics to launch a sponsored NPC GenomeComplete testing program, widening access to a specific genetic test. › Partnered with Beren Therapeutics to launch a sponsored NPC GenomeComplete testing program, widening access to a specific genetic test. 2026-09 · source CEO Katherine Stueland was named a 2026 Fierce 50 honoree, an industry recognition rather than a business change. 2026-09 · source Reported a study showing hospital-wide rapid genome sequencing increased diagnostic rates and cut time to diagnosis. 2026-08 · source Source: company newsroom Parent GeneDx Holdings Q2 revenue $114.4M, up 11% › Company reaffirmed full-year guidance of $475-490 million after steady quarterly growth. · 2026-08-03 “Revenue grew to $114.4 million, an increase of 11% year-over-year. Reiterating full year 2026 revenue guidance of $475 to $490 million.” Source: results release	Poster Fri Oct 23 2:30 pm ★ Reviewers’ Choice Part of Statistical Genetics and Genetic Epidemiology Poster Friday Session Large-Scale Gene-Based Burden Analysis Reveals the Genetic Architecture of Microcephaly in 25,000 Individuals Exhibit & Poster Hall · Board 8424F Rare variantsNeurodevelopmentalStatistical geneticsIdentification of disease genes

Organization

ASHG 2026 Attendance

GeneDx Iceland

Reykjavík, Iceland

1 presenter

Subsidiary

GeneDx provides clinical exome and genome testing, expert interpretation, and genomic data. It serves healthcare providers, health systems, patients, and biopharma partners.

Partnered with Beren Therapeutics to launch a sponsored NPC GenomeComplete testing program, widening access to a specific genetic test.

›

Partnered with Beren Therapeutics to launch a sponsored NPC GenomeComplete testing program, widening access to a specific genetic test.

2026-09 · source

CEO Katherine Stueland was named a 2026 Fierce 50 honoree, an industry recognition rather than a business change.

2026-09 · source

Reported a study showing hospital-wide rapid genome sequencing increased diagnostic rates and cut time to diagnosis.

2026-08 · source

Source: company newsroom

Parent GeneDx Holdings Q2 revenue $114.4M, up 11%

›

Company reaffirmed full-year guidance of $475-490 million after steady quarterly growth. · 2026-08-03

“Revenue grew to $114.4 million, an increase of 11% year-over-year. Reiterating full year 2026 revenue guidance of $475 to $490 million.”

Source: results release

Poster

Fri Oct 23
2:30 pm

★ Reviewers’ Choice

Part of Statistical Genetics and Genetic Epidemiology Poster Friday Session

Large-Scale Gene-Based Burden Analysis Reveals the Genetic Architecture of Microcephaly in 25,000 Individuals

Exhibit & Poster Hall · Board 8424F

Rare variantsNeurodevelopmentalStatistical geneticsIdentification of disease genes

Instantly find 20 buyers from GeneDx Iceland

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction